Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

被引：4
|
作者：
Soumerai, Jacob D. [1 ]
Diefenbach, Catherine S. [2 ]
Samaniego, Felipe [3 ]
Kumar, Abhijeet [4 ]
Tsai, Michaela L. [5 ]
Asch, Adam S. [6 ]
Jagadeesh, Deepa [7 ]
Kenkre, Vaishalee P. [8 ]
Lossos, Izidore S. [9 ]
Salman, Huda [10 ]
Awan, Farrukh T. [11 ]
Miao, Lu [12 ]
Ghalie, Richard G. [12 ]
Zelenetz, Andrew D. [13 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Lymphoma, Boston, MA 02114 USA
[2] NYU, Sch Med, NYU Canc Inst, New York, NY USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[4] Univ Arizona, Ctr Canc, Div Hematol & Oncol, Tucson, AZ USA
[5] Swedish Canc Inst, Seattle, WA USA
[6] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[7] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[9] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[10] Stony Brook Univ Hosp, Stony Brook, NY USA
[11] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[12] MEI Pharma Inc, San Diego, CA USA
[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157563
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
    Epperla, Narendranath
    Hamadani, Mehdi
    Ahn, Kwang Woo
    Oak, Eunhye
    Cashen, Amanda F.
    Kanate, Abraham Sebastian
    Calzada, Oscar
    Farmer, Zachary Luke
    Tallarico, Michael
    Nabhan, Chadi
    Costa, Luciano J.
    Kenkre, Vaishalee Padgaonkar
    Ghosh, Nilanjan
    Cohen, Jonathon Brett
    Hari, Parameswaran
    Fenske, Timothy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review
    Kahl, Brad S.
    Patel, Anik R.
    Zaidi, Omer
    Snedecor, Sonya J.
    Purdum, Anna G.
    BLOOD, 2020, 136
  • [33] Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)
    Fowler, Nathan H.
    Trotman, Judith
    Auer, Rebecca
    Flowers, Christopher R.
    Reed, William F.
    Ivanova, Elena
    Huang, Jane
    Zinzani, Pier Luigi
    BLOOD, 2019, 134
  • [34] Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
    Song, Yuqin
    Zhou, Keshu
    Zou, Dehui
    Zhou, Jianfeng
    Hu, Jianda
    Yang, Haiyan
    Zhang, Huilai
    Ji, Jie
    Xu, Wei
    Jin, Jie
    Lv, Fangfang
    Feng, Ru
    Gao, Sujun
    Guo, Haiyi
    Zhou, Lei
    Elstrom, Rebecca
    Huang, Jane
    Novotny, William
    Wei, Rachel
    Zhu, Jun
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4216 - 4224
  • [35] Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
    Fowler, Nathan H.
    Samaniego, Felipe
    Jurczak, Wojciech
    Ghosh, Nilanjan
    Derenzini, Enrico
    Reeves, James A.
    Knopinska-Posluszny, Wanda
    Cheah, Chan Y.
    Phillips, Tycel
    Lech-Maranda, Ewa
    Cheson, Bruce D.
    Caimi, Paolo F.
    Grosicki, Sebastian
    Leslie, Lori A.
    Chavez, Julio C.
    Fonseca, Gustavo
    Babu, Sunil
    Hodson, Daniel J.
    Shao, Spencer H.
    Burke, John M.
    Sharman, Jeff P.
    Law, Jennie Y.
    Pagel, John M.
    Miskin, Hari P.
    Sportelli, Peter
    O'Connor, Owen A.
    Weiss, Michael S.
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15) : 1609 - +
  • [36] Matching-Adjusted Indirect Comparison (MAIC) of efficacy and safety for tisagenlecleucel and mosunetuzumab in patients (pts) with Relapsed/Refractory (r/r) Follicular Lymphoma (FL)
    Dreyling, M.
    Fowler, N.
    Schuster, S.
    Yang, H.
    Xiang, C.
    Ramos, R.
    Maier, H.
    Jousseaume, E.
    Thieblemont, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 50 - 51
  • [37] Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL)
    Spurgeon, Stephen Edward Forbes
    Wagner-Johnston, Nina D.
    Furman, Richard R.
    Flinn, Ian
    Coutre, Steven E.
    Brown, Jennifer R.
    Benson, Don M.
    Byrd, John C.
    Leonard, John
    Peterman, Sissy
    Johnson, David Michael
    Gu, Jessie
    Dansey, Roger D.
    Godfrey, Wayne R.
    Kahl, Brad S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL)
    Freysoldt, Bianca
    Schnaiter, Andrea
    Fischer, Luca
    O'Neill, Michael
    Zimmermann, Yvonne
    Hutter, Grit
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    BLOOD, 2015, 126 (23)
  • [39] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
    G Hess
    U Keller
    C W Scholz
    M Witzens-Harig
    J Atta
    C Buske
    S Kirschey
    C Ruckes
    C Medler
    C van Oordt
    W Klapper
    M Theobald
    M Dreyling
    Leukemia, 2015, 29 : 1695 - 1701
  • [40] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
    Hess, G.
    Keller, U.
    Scholz, C. W.
    Witzens-Harig, M.
    Atta, J.
    Buske, C.
    Kirschey, S.
    Ruckes, C.
    Medler, C.
    van Oordt, C.
    Klapper, W.
    Theobald, M.
    Dreyling, M.
    LEUKEMIA, 2015, 29 (08) : 1695 - 1701
12345